Clinical trials: NSCLC Adenocarcinoma
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients
TNG462-C103 is a Phase 1/2 study to investigate the safety and antitumor activity of vopimetostat (TNG462) combined with ERAS-0015 in patients with MTAP-null pancreatic or MTAP-null non-small cell lung cancer with RAS mutation.
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation
- Trial name
- NCT07897734
- Testing
- vopimetostat, ERAS-0015
- Volunteers
- 188 people
- Sponsor
- Tango Therapeutics, Inc.
NSCLC, Prostate Cancer
Clinical Trial of TB511 in Advanced Solid Tumors
1. Study population [TB511 Monotherapy Cohort for Phase 1 and Phase 2a Clinical Trial] Patients with advanced solid tumors who are either refractory or intolerant to standard of care (SoC).
- Conditions
- NSCLC, Prostate Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06400160
- Testing
- TB511, Keytruda
- Volunteers
- 12 people
- Sponsor
- Twinpig Biolab, Inc.
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
- Conditions
- Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05902988
- Testing
- VLS-1488
- Where
- 14 sites in United States
- Volunteers
- 200 people
- Sponsor
- Volastra Therapeutics, Inc.
Solid Tumor, NSCLC
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
This is a first-in-human, multicenter, open-label Phase 1/2 study designed to evaluate the safety, efficacy, and tolerability of [225Ac]Ac-FL-261, a targeted radioligand therapy directed at c-MET, in participants with advanced or…
- Conditions
- Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT07873450
- Testing
- [225Ac]Ac-FL-261
- Where
- 2 sites in United States, Australia
- Volunteers
- 208 people
- Sponsor
- Full-Life Technologies UK Limited
Cutaneous Melanoma, Non-small Cell Lung Cancer
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
In this study, Genocea is evaluating an investigational, personalized adjuvanted vaccine, GEN-009, that is being developed for the treatment of patients with solid tumors.
- Conditions
- Cutaneous Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Urothelial Carcinoma
- Trial name
- NCT03633110
- Testing
- GEN-009 Adjuvanted Vaccine, Nivolumab, Pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genocea Biosciences, Inc.
Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer
A Phase I/II study of an in-situ therapeutic cancer vaccine. Vaccines contain a source of antigen and and adjuvant. In this study the source of tumor antigen comes from the killing of a selected tumor by cryoablation (killing…
- Conditions
- Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT01065441
- Testing
- AlloStim, Cryoablation
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Michael Har-Noy
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
This phase II clinical trial studies how well combining different regimens of chemotherapy and gefitinib with radiation therapy work in treating patients with stage III non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT00040794
- Testing
- paclitaxel, carboplatin, gefitinib
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- National Cancer Institute (NCI)
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that…
- Conditions
- Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT04929041
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 169 sites in United States
- Volunteers
- 427 people
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer, Adenocarcinoma
Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers
Intercalated administration of Iressa® (gefitinib) on days 5-18 of chemotherapy cycle improve the efficacy of Pemetrexed/platinum regimen given as first-line treatment for never-smokers with advanced (stage IIIB/IV) lung…
- Trial name
- NCT01502202
- Testing
- Gefitinib, Pemetrexed plusCIsplatin
- Where
- South Korea
- Volunteers
- 162 people
- Sponsor
- National Cancer Center, Korea
Lung Cancer
Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with surgery may kill more tumor cells.
- Trial name
- NCT00003231
- Testing
- cisplatin, docetaxel, surgical procedure
- Where
- 9 sites in Switzerland
- Volunteers
- 40 people
- Sponsor
- Swiss Cancer Institute
Non-Small Cell Lung Cancer
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
This Phase III study will be conducted to evaluate the efficacy and safety of YH25448 as first-line treatment in locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) patients with EGFR mutations
- Trial name
- NCT04248829
- Testing
- Lazertinib 240 mg/160 mg, Gefitinib 250 mg
- Where
- 80 sites in Australia, Greece and 11 more
- Volunteers
- 393 people
- Sponsor
- Yuhan Corporation
Melanoma, Urothelial Carcinoma
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Safety study of RC198 in Subjects with Solid Tumors.
- Conditions
- Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT05867303
- Testing
- RC198 Injection
- Where
- 5 sites in Australia, China
- Volunteers
- 48 people
- Sponsor
- RemeGen Co., Ltd.
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Advanced Solid Tumors
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of budigalimab.
- Trial name
- NCT03000257
- Testing
- Venetoclax, Rovalpituzumab Tesirine, ABBV-181
- Where
- 26 sites in United States, Australia and 8 more
- Volunteers
- 182 people
- Sponsor
- AbbVie
HER2-Expressing Solid Tumors
Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
This clinical trial is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of MT-304 in adults with advanced HER2-expressing solid tumors.
- Trial name
- NCT07334119
- Testing
- MT-304, MT-304 + Nivolumab
- Where
- 7 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Myeloid Therapeutics
Lung Cancer
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00103207
- Testing
- cetuximab
- Where
- 157 sites in United States
- Volunteers
- 72 people
- Sponsor
- Eastern Cooperative Oncology Group
Lung Cancer
The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting
The goal of this clinical research study is to learn if it is tolerable for patients with NSCLC to receive afatinib before surgery. The safety of this drug will also be studied.
- Trial name
- NCT02271906
- Testing
- BIBW 2992
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer (NSCLC), EGFR Activating Mutation
Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data
The main purpose of this study is to explore the value of multimodal imaging information and models in predicting the prognosis of EGFR-positive non-small cell lung cancer patients undergoing targeted therapy, providing a basis…
- Conditions
- Lung Cancer (NSCLC), EGFR Activating Mutation, Adenocarcinoma Lung, Postoperative Adjuvant Therapy
- Trial name
- NCT07287904
- Testing
- Comprehensive analysis through laboratory tests, imaging techniques, and clinical data
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Advanced Cancer, Gastric Adenocarcinoma
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
The purpose of this study is to find a recommended schedule and dose range for Emibetuzumab when given with ramucirumab that may be safely given to participants with cancer.
- Conditions
- Advanced Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Hepatocellular Cancer
- Trial name
- NCT02082210
- Testing
- Emibetuzumab, Ramucirumab
- Where
- 4 sites in United States
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG